Tracking Health Indicators After COVID-19 Requires Real-Time Capabilities

Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their pharmacies through network exclusions and targeted marketing.

Jessica Tracy, head of Growth and Partnerships at Enthea, shares how employers and unions can support mental health and address access barriers to evidence-based ketamine treatments.

The COVID-19 pandemic accelerated the widespread adoption of telemental health care, and new research indicates significant racial and ethnic disparities in access to this technology among Medicaid beneficiaries with schizophrenia.

Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.

Patients who revisit the emergency department shortly after discharge are at high risk for complications and death, exacerbated by COVID-19 screening workload. Detection efforts impact outcomes.

In part 2 of our interview with Karen Winkfield, MD, PhD, she speaks to the importance of ensuring health care accessibility and of knowing that the health care system is not a one-size-fits-all arrangement.